A real-world cost-effectiveness study of vancomycin versus linezolid for the treatment of late-onset neonatal sepsis in the NICU in China

A real-world cost-effectiveness study of vancomycin versus linezolid for the treatment of late-onset neonatal sepsis in the NICU in China

Abstract Background and objective Currently, the detection rates of methicillin-resistant S. aureus (MRSA) and methicillin-resistant coagulase-negative staphylococci (MRCoNS) in the blood cultures of neonates with sepsis exceed the national average drug resistance level, and vancomycin and linezolid...

Full description

Bibliographic Details
Main Authors: Linjun Xie, Leyun Ding, Lian Tang, Zuming Yang, Dan Wu, Wenjuan Wang, Juehui Mao, Lu Shi, Chun Liu, Lufen Duan, Jinhui Xu, Qin Zhou, Jiantong Sun, Xinyuan Ding
Format: Article
Language:English
Published: BMC 2023-07-01
Series:BMC Health Services Research
Subjects:
Neonatal sepsis
Vancomycin
Linezolid
Real-world
Cost-effectiveness analysis
Online Access:https://doi.org/10.1186/s12913-023-09628-9

Internet

https://doi.org/10.1186/s12913-023-09628-9

Similar Items